Immudex

Immudex is a Danish life-science company focused on reagents and diagnostic applications for cellular immunology. The company develops MHC Dextramers, fluorescent major histocompatibility complex multimer reagents used with flow cytometry to identify, quantify, and in some cases isolate antigen-specific T cells. Its technology is primarily directed at CD8+ T-cell responses presented through MHC class I molecules, with coverage extending across selected human, mouse, and monkey alleles and disease-relevant antigenic peptides. The business originated within Dako, the Danish pharmaceutical and diagnostics company. Patents for the underlying MHC Dextramer technology were filed at Dako in 2001, and the Immudex division was launched in 2005. As Dako increasingly concentrated on cancer diagnostics, the division was spun out as a separate company. Immudex was established as an independent business in 2009 and developed an international customer base, particularly in the United States and Europe. The company has operated from offices in Copenhagen and Fairfax, Virginia. Immudex's central technology uses a dextran backbone carrying multiple MHC-peptide complexes. Whereas conventional tetramers provide four binding sites, Dextramers generally provide nine or more, increasing the probability of binding and enabling sensitive detection of low-frequency antigen-specific T cells. This is relevant to research and clinical development programs in infectious disease, cancer immunology, transplantation, vaccines, and immunotherapy, where investigators need to characterize T-cell responses before, during, and after treatment. The company's portfolio has included virus-focused reagents for cytomegalovirus, Epstein-Barr virus, influenza, and BK virus; melanoma-associated antigen reagents; and CD1d Dextramers loaded with alpha-galactosylceramide for identifying and sorting natural killer T cells. Immudex has also developed a CE-marked Dextramer CMV kit for clinical in-vitro diagnostic use in Europe. The kit is intended to enumerate CMV-specific CD8+ T cells in whole-blood samples and to assist assessment of CMV-specific immune status, including in HLA-matched patients and populations at risk of CMV-related disease. Although a substantial part of the portfolio has been sold for research use only, Immudex has pursued clinical applications. Its development work has included efforts to support broader clinical use of the CMV kit and diagnostic programs based on detecting Borrelia-specific T cells in patients with Lyme disease or borreliosis. The company has also indicated interest in extending the Dextramer platform toward MHC class II applications, which could broaden the range of immune-cell responses studied. Immudex has complemented its product development with collaborations intended to improve immune-monitoring workflows. In 2013, it entered a co-distribution and co-promotion arrangement with JPT Peptide Technologies, combining JPT's peptide capabilities with Immudex's MHC Dextramer products. In the same period, Immudex agreed to provide MHC-peptide multimer and ELISpot proficiency panels through arrangements involving the US Cancer Immunotherapy Consortium and the European Association for Cancer Immunotherapy. These panels were designed to support interlaboratory quality assessment and harmonization of flow-cytometry-based MHC multimer and ELISpot assays. Immudex's role positioned the company not only as a reagent supplier but also as a participant in standardization efforts for immune monitoring in cancer, vaccine, infectious-disease, and other immunology research.

Immudex developed from an internal technology and business initiative at Dako, a Danish pharmaceutical and diagnostics company. The underlying MHC Dextramer patents were filed at Dako in 2001. The Immudex division was launched in 2005, during a period when the technology was being organized as a dedicated activity within Dako. Dako later placed greater emphasis on cancer diagnostics, leading to the division's separation and the creation of Immudex as an independent company in 2009. The company's core proposition was based on improving the sensitivity of MHC multimer assays. MHC multimers bind T-cell receptors that recognize particular peptide-MHC combinations, allowing researchers to identify antigen-specific T cells with flow cytometry. Earlier tetramer formats used four binding sites. Immudex's Dextramer architecture used a dextran backbone with nine or more MHC-peptide binding sites, intended to increase avidity and improve the likelihood of detecting rare or weakly represented antigen-specific cells. The platform was especially focused on MHC class I and CD8+ T-cell responses, although the company also identified MHC class II as a possible area for expansion. Immudex built a portfolio of research reagents for infectious-disease and cancer immunology. Its virus collection included reagents for CMV, EBV, influenza, and BK virus. Other offerings addressed melanoma-associated antigens and CD1d-restricted natural killer T-cell identification. These products were designed for detection, enumeration, and, where appropriate, isolation of antigen-specific cells from blood or tumor tissue. The technology was relevant to the development of vaccines and immunotherapies because researchers could measure cellular immune responses before, during, and after treatment. A significant stage in the company's development was the move toward clinical diagnostics. Immudex developed a CE-marked Dextramer CMV kit for European clinical in-vitro diagnostic use. The kit was designed to enumerate CMV-specific CD8+ T cells in whole blood and to help evaluate CMV-specific immune status in patients with relevant HLA types. Such testing is particularly pertinent to immunocompromised people, including organ-transplant recipients and people with HIV infection, for whom CMV disease can be serious even when infection is less apparent in healthy individuals. Immudex also pursued further clinical development and potential regulatory approval for the United States. The company expanded beyond commercial reagents through development work in Lyme disease or borreliosis, using the proposed detection of Borrelia-specific T cells as a diagnostic avenue. It also participated in external quality and assay-standardization initiatives. In 2013, Immudex entered a co-distribution and co-promotion partnership with JPT Peptide Technologies. The arrangement was intended to combine JPT's peptide technology with Immudex's Dextramer products and services for the immunotherapy and vaccine communities. During 2013, Immudex also entered an agreement involving the Cancer Immunotherapy Consortium and the European Association for Cancer Immunotherapy to provide proficiency panels. These programs used interlaboratory testing to assess performance and improve harmonization in MHC multimer flow-cytometry assays and ELISpot assays. The initiative extended Immudex's role into quality assurance and methodological standardization, supporting laboratories working in cancer immunotherapy and other fields of immune monitoring. Immudex received Ernst & Young's Life Sciences Entrepreneur of the Year award in 2011. The award recognized the company's stated commitment to a strategy centered on making its technology work and improving it, as well as its broader organizational and social responsibilities. The company has served customers internationally, with the United States and Europe identified as major markets. Publicly described activities show a business spanning research-use-only reagents, clinical diagnostic development, immune-monitoring services, and collaborations supporting assay harmonization.

1. 2013JPT distribution and promotion partnership

   Immudex and JPT Peptide Technologies established a co-distribution and co-promotion partnership.

   Source
2. 2013International proficiency-panel agreement

   Immudex entered arrangements to provide MHC multimer and ELISpot proficiency panels to laboratories worldwide.

   Source
3. 2011Life Sciences Entrepreneur of the Year recognition

   Immudex received Ernst & Young's Entrepreneur of the Year 2011 award in the Life Sciences category.

   Source
4. 2009Immudex established as an independent company

   The Immudex business was spun out of Dako as Dako concentrated more heavily on cancer diagnostics.

   Source
5. 2005Immudex division launched within Dako

   Dako launched an Immudex division to develop and commercialize the MHC Dextramer technology.

   Source
6. 2001MHC Dextramer technology patents filed at Dako

   Patents covering the technology that later formed the basis of Immudex's MHC Dextramer platform were filed within Dako.

   Source

A specialist immunology-tools and diagnostics provider using multivalent MHC Dextramer technology to enable sensitive detection, enumeration, characterization, and isolation of antigen-specific T cells.

• MHC Dextramer reagentsResearch reagents

  Fluorescent MHC multimer reagents used with flow cytometry to detect, quantify, characterize, and potentially isolate antigen-specific T cells. The platform is primarily oriented toward MHC class I and CD8+ T-cell responses and includes selected human, mouse, and monkey alleles carrying disease-relevant peptides.

• Virus Dextramer Collection 1Infectious-disease research reagents

  A collection of Dextramer reagents for detecting, enumerating, and isolating virus-specific T cells. The described coverage includes cytomegalovirus, Epstein-Barr virus, influenza virus, and BK virus, supporting immune-response monitoring in research settings.

• Dextramer CMV kitClinical in-vitro diagnostic kit

  A CE-marked clinical reagent kit intended to enumerate CMV-specific CD8+ T cells in whole-blood samples. It is designed to assist assessment of CMV-specific immune status and monitoring of patients at risk of CMV-related disease, including appropriately HLA-matched patients.

• Melanoma Dextramer Collection 1Cancer research reagents

  A set of MHC Dextramers directed at six melanoma-associated antigens. The reagents are intended for detection, enumeration, and isolation of melanoma-specific CD8+ T cells from blood or tumor tissue in research applications.

• Cancer Testis Antigen CD1d DextramerNatural killer T-cell research reagent

  A flow-cytometry reagent displaying human CD1d molecules loaded with alpha-galactosylceramide. It is designed to identify and sort natural killer T cells and forms part of a wider range of reagents for cancer- and virus-specific immune-cell detection.

• 2013Co-distribution and co-promotion agreement with JPTOther

  Immudex sought to broaden the offering available to the immunotherapy and vaccine research community by combining its MHC Dextramer technology with complementary peptide capabilities.

  What changed. Immudex entered a co-distribution and co-promotion partnership with JPT Peptide Technologies.

  Aftermath. The partnership was intended to create a broader portfolio of T-cell-relevant products and services.

  Source
• 2009Spin-out from DakoStrategy

  Dako shifted substantial attention toward cancer diagnostics, while the Immudex technology represented a distinct immunology-reagents and diagnostics opportunity.

  What changed. The Immudex division was separated from Dako and established as an independent company.

  Aftermath. Immudex continued developing MHC Dextramer research products, clinical applications, international distribution, and assay-standardization activities.

  Source

• 2013Immudex partners with JPT Peptide Technologies

  Immudex entered a co-distribution and co-promotion partnership with JPT Peptide Technologies to combine peptide products and services with Immudex's MHC Dextramer portfolio for immunotherapy and vaccine research.

  Other
  Source
• 2013Immudex enters immune-monitoring proficiency-panel arrangements

  Immudex entered arrangements involving the Cancer Immunotherapy Consortium and the European Association for Cancer Immunotherapy to provide MHC-peptide multimer and ELISpot proficiency panels to laboratories internationally.

  Other
  Source
• 2011Immudex receives Life Sciences Entrepreneur of the Year award

  Immudex received Ernst & Young's Entrepreneur of the Year 2011 award in the Life Sciences category. The recognition cited the company's results-oriented strategy and attention to organizational and social values.

  Other
  Source

1. Immudex